openPR Logo
Press release

Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts - MRH

04-06-2017 12:08 PM CET | Health & Medicine

Press release from: Market Research Provider - MRH

Market Research Hub

Market Research Hub

The "Global Companion Diagnostics Partnering" 2010-2017 report provides a comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049036

Trends in companion diagnostics partnering deals
Companion diagnostics partnering agreement structure
Companion diagnostics partnering contract documents
Top companion diagnostics deals by value
Most active companion diagnostics dealmakers

The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to the commercialization of outcomes.

This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.

The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments, and royalties, enabling readers to analyze and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 350 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.

Key benefits

Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Companion Diagnostics deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies
Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
Identify most active Companion Diagnostics dealmakers since 2010
Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Companion Diagnostics trends and structure of deals entered into by leading companies worldwide.

Companion Diagnostics Partnering Terms and Agreements includes:

Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010
Analysis of Companion Diagnostics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Companion Diagnostics deals
Access to Companion Diagnostics contract documents
Leading Companion Diagnostics deals by value since 2010
Most active Companion Diagnostics dealmakers since 2010

In Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 350 Companion Diagnostics deals.

Browse Full Report with TOC: http://www.marketresearchhub.com/report/global-companion-diagnostics-partnering-2010-2017-deal-trends-players-financials-and-forecasts-report.html

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Follow Us on:
Twitter: https://twitter.com/MktResearchHub/
LinkedIn: https://www.linkedin.com/company/market-research-hub/
Facebook : https://www.facebook.com/MarketResearchHub/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Companion Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts - MRH here

News-ID: 493665 • Views: 189

More Releases from Market Research Provider - MRH

Global Sports Accessories Market Status & Growth Analysis Forecasted till 2022
Market Research Hub (MRH) has included a new report titled “Global Sports Accessories Market Research Report 2017”, to its huge database. This research study includes information about the regional production along with revenue and market share. The report further updates that the sports market on the global level would acquire a rise at a positive CAGR during the period 2017-2022, which is surely a major boost for the concerned sector.
Global Film Release Liners Market to Rise at an Impressive Rate during the Forec …
The demand for film release liners is greatly influenced by the advancements in the packaging industry. The increased preference for modern and latest packaging all across the world, coupled with the increasing investments in the pharmaceuticals and the food and beverages industries, is expected to drive the demand in the global market for film release liners over the coming years. A new market report with a title “Global Film Release
Global Coated Graphite Market Status, Trends & Future Outlook until 2022
The latest research report added to the vast database of Market Research Hub (MRH). The study is titled “Global Coated Graphite Market Research Report 2017”, which includes information about the regional segmentation on the basis of factors such as production, consumption, revenue, and market share. It is also mentioned that the market would soon acquire growth at a double-digit CAGR between 2017 and 2022. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1217172 Geographically, this

More Releases for Companion

Companion Animal Drugs - Key Market Statistics
Companion animals are pets kept primarily for company, entertainment, and safety. Owners of companion animals consider them to be family, friends, and confidants. Dogs, cats, birds, rabbits, horses, goats, gerbils, rats, mice, and amphibians, others are considered as companion animals. Read Report Overview - https://www.transparencymarketresearch.com/companion-animal-specialty-drugs-market.html According to the American Society for the Prevention of Cruelty to Animals (ASPCA) defines companion animal to be domesticated or domestically-bred whose emotional, physical, social, and behavioral
Companion Animal Vaccine – Improving The Health Of Companion Animals In A Cost …
The companion animal vaccines market is expected to witness significant growth during the forecast period due to launch of vaccines for companion animals. For instance, in December 2017, Zoetis Inc. announced the launch of Vanguard CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against the two strains of the virus known to be circulating in the U.S. Moreover, the
Companion Diagnostics Market - Easing of Regulatory Policies to Drive Global Dem …
Companion diagnostics include two types of tests namely tests which are developed along with target drugs and the other developed after the commercialization of drugs. Companion diagnostics combined with targeted therapeutics are being seen as a major breakthrough in the personalized medicine field. Companies operating in the companion diagnostics market are seeking an effective growth strategy in the development of this concept drug-diagnostic interaction as the healthcare sector is shifting
Global Companion Diagnostics Market
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test
Global Companion Diagnostics – Growth Companion for Personalized Medicine
Companion Diagnostics: Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy.
Companion diagnostics Market: Companion diagnostic are used to determine patient …
The few companion diagnostics are already available in the market for specific types of cancer and many are already under clinical development. Companion diagnostics test depends on finding a specific biomarker in the patient and hence biomarker presence or absence determines whether or not the patient will respond to the treatment. This test require a biopsied tissue to access the expression of biomarker protein or mutant or aberrant genes. Companion